Glen Research

Executive Summary

Glen Research is a specialized supplier of chemical reagents and solid supports for the synthesis, modification, and purification of DNA and RNA oligonucleotides. Founded in 1983 and based in Sterling, Virginia, the company serves the genetics, genomics, and diagnostics research sectors by providing essential building blocks for oligonucleotide manufacturing. Its product portfolio includes phosphoramidites, nucleosides, fluorophores, quenchers, and various modifiers used in automated synthesis. As a private company with a long operating history, Glen Research benefits from the growing demand for oligonucleotides in research, diagnostics, and therapeutic applications. The global oligonucleotide synthesis market is expanding at a double-digit CAGR, driven by advances in antisense and siRNA therapies, which directly increases demand for Glen Research's core products. However, the company faces competition from larger chemical suppliers and potential disruption from new synthesis technologies such as enzymatic synthesis. Limited public information restricts detailed financial assessment, but the company's niche focus and established reputation in the oligo supply chain suggest stable, albeit moderate, growth prospects. Overall, Glen Research represents a steady, low-profile investment opportunity in the genomics tools space.

Upcoming Catalysts (preview)

• Q3 2026New Product Launches in Fluorophores and Quenchers for Next-Gen Sequencing65% success